Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in Daily Practice

Introduction. Liraglutide is a GLP-1 receptor agonist that has been recently added to the therapeutic armamentarium for the treatment of diabetes type 2. It is prioritaire to evaluate the long-term impact of a new therapy when used under routine clinical practice conditions

Aims. The REAL study has been designed in order to evaluate whether the clinical results of metabolic control, obesity indices and cardiovascular risk factors obtained in the approval trials were confirmed in an Italian setting of routine clinical practice. The study also allowed the evaluation of the ver time persistence of the obtained benefits and the exploratory analyses on the use of the drug and its impact in specific subgroups. Finally, in-depth analyses were conducted aimed at identifying factors associated with the reduction in glycated hemoglobin

Type of study. Observational, longitudinal, multicenter study

Population. 1,723 patients with type 2 diabetes starting treatment with liraglutide in 2011, followed up for 24 months

Centers. 45 Italian diabetes centers

Promoter. NovoNordisk SpA, Italy

Funding. NovoNordisk SpA, Italy

Status. Study completed


  1. Lapolla A, Berra C, Boemi M, Bossi AC, Candido R, Di Cianni G, Frontoni S, Genovese S, Ponzani P, Provenzano V, Russo GT, Sciangula L, Simioni N, Bette C, Nicolucci A; NN2211-4118 Study Group. Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in a Real-Life Setting: A 24-Month, Multicenter, Non-interventional, Retrospective Study. Adv Ther 2018; 35: 243-253.